Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV001820401 | SCV002071234 | uncertain significance | not specified | 2019-10-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002542619 | SCV003033203 | likely benign | not provided | 2024-03-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004040985 | SCV005002861 | uncertain significance | Inborn genetic diseases | 2023-11-02 | criteria provided, single submitter | clinical testing | The c.236C>T (p.P79L) alteration is located in exon 2 (coding exon 2) of the PCNT gene. This alteration results from a C to T substitution at nucleotide position 236, causing the proline (P) at amino acid position 79 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004741092 | SCV005347206 | uncertain significance | PCNT-related disorder | 2024-08-14 | no assertion criteria provided | clinical testing | The PCNT c.236C>T variant is predicted to result in the amino acid substitution p.Pro79Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.065% of alleles in individuals of South Asian descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |